Transcriptomic data analysis of melanocytes and melanoma cell lines of LAT transporter genes for precise medicine

Транскриптомный анализ экспрессии генов LAT-транспортеров в меланоцитах и клеточных линиях меланомы для прецизионной медицины
Małgorzata Przybyło, Paweł Moskal, Ewa Łucja Stępień, Dominik Panek, Monika Szczepanek
2022-12-01

Boron Neutron Capture TherapyLAT transporter genesSLC3A2 (4Fhc)SLC7A5 (LAT1)boronophenylalanine uptake
Abstract Background: Boron Neutron Capture Therapy (BNCT) is a two-step treatment that can be used in some types of cancers. It involves administering a compound containing boron atoms to the patient and irradiating the affected area of the body with a neutron beam. The success of the therapy depends mainly on the delivery of the boron isotope (10B) to the tumor using an appropriate boron carrier. One of the boron carriers used is boronophenylalanine (BPA). Therefore, in research on the use of boron carriers, it is also important to know the mechanisms of its uptake by cells. Aim: To study the expression of LAT family genes in two melanoma (high melanotic WM115 and low melanotic WM266-4) cell lines and melanocytes (HEMa-Lp) which are responsible for the transport the BPA into cells. Methods: To normalize data from the transcriptomic analysis, the ratio of the median method was used. This allowed the samples to be compared with each other. Comparison metrics included log-fold change (LFC) values. The heatmap of LFC values and the cluster map were created. These graphs show the similarities and differences between the samples. Results: Transcriptomic data show that in melanocytes, LFC for SLC7A5 (LAT1) and SLC3A2 (4Fhc) was higher than in melanoma cell lines, which corresponded with their melanin content. Conclusion: Our results indicate overexpression of BPA transporter genes in normal cells (melanocytes), which may suggest the highest level of these proteins in melanocytes compared to less melanotic melanoma. Therefore, for BNCT, the use of BPA as the 10B carrier will require additional qualifying tests of amino acid transporter expression for patients and specific tumors to develop a personalized BNCT.
1
Higher LAT1 and 4Fhc expression in melanocytes corresponded with their greater melanin content compared with melanoma cells.
2
Melanocytes showed higher log-fold changes for SLC7A5 (LAT1) and SLC3A2 (4Fhc) than both melanoma cell lines.
3
Personalized BNCT using BPA may require patient- and tumor-specific qualification of amino acid transporter expression.
4
The findings indicate that BPA transporter proteins may be more highly expressed in normal melanocytes than in less-melanotic melanoma cells.
5
The study analyzed LAT-family transporter gene expression in melanocytes and highly versus weakly melanotic melanoma cell lines to assess potential BPA uptake mechanisms.

LAT transporter gene expression in melanocytes and melanoma cell lines (WM115 and WM266-4)

Differences in expression of BPA-transporting LAT family genes, particularly SLC7A5 (LAT1) and SLC3A2 (4Fhc), in relation to cellular melanin content and implications for BPA delivery in BNCT

Publication Details
Publication Date
2022-12-01
Journal
Publisher
ISSN
Cited by
7
Access Type
Author Information
Authors
Małgorzata Przybyło
Paweł Moskal
Ewa Łucja Stępień
Dominik Panek
Monika Szczepanek
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%